These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 39048905)

  • 1. ALLIANCE A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.
    Eade AV; Friedman LR; Larrain C; Rainey A; Hernandez JM; Chawla A; Ferrone CR
    Ann Surg Oncol; 2024 Oct; 31(10):6373-6374. PubMed ID: 39048905
    [No Abstract]   [Full Text] [Related]  

  • 2. Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?
    Kim MP; Katz MHG
    Ann Surg Oncol; 2019 Jun; 26(6):1596-1597. PubMed ID: 30680479
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
    Goetze TO; Reichart A; Bankstahl US; Pauligk C; Loose M; Kraus TW; Elshafei M; Bechstein WO; Trojan J; Behrend M; Homann N; Venerito M; Bohle W; Varvenne M; Bolling C; Behringer DM; Kratz-Albers K; Siegler GM; Hozaeel W; Al-Batran SE
    Ann Surg Oncol; 2024 Jun; 31(6):4073-4083. PubMed ID: 38459418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative Chemotherapy for Pancreas Cancer: Quo Vadis?
    Patel RK; Rocha FG
    Ann Surg Oncol; 2024 Jul; 31(7):4176-4178. PubMed ID: 38652201
    [No Abstract]   [Full Text] [Related]  

  • 6. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
    Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501).
    Snyder RA; Zemla TJ; Shi Q; Segovia D; Ahmad SA; O'Reilly EM; Herman JM; Katz MHG
    Ann Surg Oncol; 2024 Oct; 31(10):7033-7042. PubMed ID: 39008208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?
    Reni M
    World J Gastroenterol; 2010 Oct; 16(39):4883-7. PubMed ID: 20954273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
    Katz MHG; Ou FS; Herman JM; Ahmad SA; Wolpin B; Marsh R; Behr S; Shi Q; Chuong M; Schwartz LH; Frankel W; Collisson E; Koay EJ; Hubbard JM; Leenstra JL; Meyerhardt J; O'Reilly E;
    BMC Cancer; 2017 Jul; 17(1):505. PubMed ID: 28750659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
    Hagiwara Y; Ohashi Y; Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T;
    Eur J Cancer; 2018 Apr; 93():79-88. PubMed ID: 29477795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant chemotherapy for resectable pancreatic cancer].
    Unno M
    Nihon Shokakibyo Gakkai Zasshi; 2020; 117(4):297-301. PubMed ID: 32281569
    [No Abstract]   [Full Text] [Related]  

  • 15. Perioperative chemotherapy with modified FOLFIRINOX for nonmetastatic pancreatic cancer: a new standard of care?
    Radi I; Samaha R; El Hajj J; Samaha H; Kourie HR
    Future Oncol; 2021 Jan; 17(3):229-233. PubMed ID: 33305614
    [No Abstract]   [Full Text] [Related]  

  • 16. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
    Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
    JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy for pancreatic cancer: current status and future directions.
    Xiong HQ; Abbruzzese JL
    Surg Oncol Clin N Am; 2004 Oct; 13(4):737-49, xi. PubMed ID: 15350945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case for routine use of adjuvant therapy in pancreatic cancer.
    Kennedy EP; Yeo CJ
    J Surg Oncol; 2007 Jun; 95(7):597-603. PubMed ID: 17230543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
    Drudi F; Tassinari D; Giuliani J; Ridolfi C; Gianni L; Tamburini E; Fantini M; Santelmo C; Barzotti E; Lotti N; Ravaioli A
    Recenti Prog Med; 2013 Feb; 104(2):80-5. PubMed ID: 23535964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.